IN2013MN02443A - - Google Patents

Download PDF

Info

Publication number
IN2013MN02443A
IN2013MN02443A IN2443MUN2013A IN2013MN02443A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A IN 2443MUN2013 A IN2443MUN2013 A IN 2443MUN2013A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A
Authority
IN
India
Prior art keywords
pyrroloquinolinyl
pyrrole
dione
formulations
administering
Prior art date
Application number
Other languages
English (en)
Inventor
Hiroshi Yamakose
Takafumi Kato
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of IN2013MN02443A publication Critical patent/IN2013MN02443A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2443MUN2013 2011-07-07 2012-07-06 IN2013MN02443A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505175P 2011-07-07 2011-07-07
PCT/US2012/045688 WO2013006761A2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Publications (1)

Publication Number Publication Date
IN2013MN02443A true IN2013MN02443A (zh) 2015-06-12

Family

ID=47437711

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2443MUN2013 IN2013MN02443A (zh) 2011-07-07 2012-07-06

Country Status (14)

Country Link
US (2) US9180099B2 (zh)
EP (1) EP2729145A4 (zh)
JP (1) JP6073310B2 (zh)
KR (1) KR20140146036A (zh)
CN (1) CN103930110A (zh)
AU (1) AU2012278831A1 (zh)
BR (1) BR112013033807A2 (zh)
CA (1) CA2839584A1 (zh)
IN (1) IN2013MN02443A (zh)
MX (1) MX2014000253A (zh)
PH (1) PH12015501980A1 (zh)
TW (1) TW201315470A (zh)
WO (1) WO2013006761A2 (zh)
ZA (1) ZA201400108B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289892B1 (en) * 2005-02-09 2012-08-22 ArQule, Inc. Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
TW201350483A (zh) * 2012-04-23 2013-12-16 Arqule Inc 高純度吡咯並喹啉基－吡咯－２，５－二酮及吡咯並喹啉基－吡咯啶－２，５－二酮以及彼等之製備方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
BR0111747A (pt) * 2000-06-28 2003-07-08 Smithkline Beecham Plc Processo de moagem úmida
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
EP2289892B1 (en) 2005-02-09 2012-08-22 ArQule, Inc. Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
CN101474175B (zh) * 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
CN102481299B (zh) 2009-02-12 2015-02-25 艾科尔公司 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
SG181927A1 (en) * 2009-12-23 2012-07-30 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
ZA201400108B (en) 2016-03-30
WO2013006761A2 (en) 2013-01-10
CN103930110A (zh) 2014-07-16
JP2014518284A (ja) 2014-07-28
PH12015501980A1 (en) 2017-10-18
TW201315470A (zh) 2013-04-16
MX2014000253A (es) 2014-10-17
US9180099B2 (en) 2015-11-10
EP2729145A4 (en) 2014-12-10
US20130011481A1 (en) 2013-01-10
CA2839584A1 (en) 2013-01-10
AU2012278831A1 (en) 2014-01-16
US20160022667A1 (en) 2016-01-28
EP2729145A2 (en) 2014-05-14
BR112013033807A2 (pt) 2017-02-14
KR20140146036A (ko) 2014-12-24
WO2013006761A3 (en) 2013-04-18
JP6073310B2 (ja) 2017-02-01

Similar Documents

Publication Publication Date Title
PH12018501410A1 (en) Therapeutically active compounds and their method of use
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX344530B (es) Compuestos de benceno substituido.
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
PH12015500825B1 (en) Substituted benzene compounds
CR20200479A (es) COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069)
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
IN2013MN02443A (zh)
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.